- Home
- ATEX vs NUVB Comparison
ATEX vs NUVB Comparison
Compare ATEX & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATEX
- NUVB
- Stock Information
- Founded
- ATEX 1997
- NUVB 2018
- Country
- ATEX United States
- NUVB United States
- Employees
- ATEX N/A
- NUVB N/A
- Industry
- ATEX Telecommunications Equipment
- NUVB Biotechnology: Pharmaceutical Preparations
- Sector
- ATEX Telecommunications
- NUVB Health Care
- Exchange
- ATEX Nasdaq
- NUVB Nasdaq
- Market Cap
- ATEX 718.0M
- NUVB 679.9M
- IPO Year
- ATEX N/A
- NUVB N/A
- Fundamental
- Price
- ATEX $28.82
- NUVB $2.10
- Analyst Decision
- ATEX Buy
- NUVB Strong Buy
- Analyst Count
- ATEX 2
- NUVB 5
- Target Price
- ATEX $64.00
- NUVB $8.20
- AVG Volume (30 Days)
- ATEX 112.0K
- NUVB 3.2M
- Earning Date
- ATEX 06-25-2025
- NUVB 05-07-2025
- Dividend Yield
- ATEX N/A
- NUVB N/A
- EPS Growth
- ATEX N/A
- NUVB N/A
- EPS
- ATEX N/A
- NUVB N/A
- Revenue
- ATEX $5,902,000.00
- NUVB $10,957,000.00
- Revenue This Year
- ATEX $49.39
- NUVB $75.73
- Revenue Next Year
- ATEX $2.84
- NUVB $440.21
- P/E Ratio
- ATEX N/A
- NUVB N/A
- Revenue Growth
- ATEX 66.77
- NUVB N/A
- 52 Week Low
- ATEX $27.37
- NUVB $1.54
- 52 Week High
- ATEX $42.91
- NUVB $3.97
- Technical
- Relative Strength Index (RSI)
- ATEX 31.15
- NUVB 50.80
- Support Level
- ATEX $27.31
- NUVB $1.98
- Resistance Level
- ATEX $29.52
- NUVB $2.30
- Average True Range (ATR)
- ATEX 1.05
- NUVB 0.16
- MACD
- ATEX 0.07
- NUVB -0.01
- Stochastic Oscillator
- ATEX 35.12
- NUVB 21.43
About ATEX Anterix Inc.
Anterix Inc is a United States-based company engaged in delivering broadband needed to modernize infrastructure for energy, transportation, logistics, and other industries. The company offers Private LTE for utilities which help to automate processes, monitor environmental conditions, enable artificial intelligence, and drive productivity.
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).